Evolution of the Average Target: West Pharmaceutical Services, Inc.

Evolution of the Average Target - West Pharmaceutical Services, Inc.

Evolution of the Target Price: West Pharmaceutical Services, Inc.

Evolution of the Target Price - West Pharmaceutical Services, Inc.

Changes in Analyst Recommendations: West Pharmaceutical Services, Inc.

77.gTjTTX1TgyEmibAWjJbDfrf_iWiqWnn7aIutX28-Qz8.9w65DDAA63lSzf94y6SsMvWVvzLlGDuoEdvAHVhOdnDeeaU5HyauTkjE_Q~5d7b55c27d1cb85c017823ebe5adb7f5
10-06 Barclays Raises West Pharmaceutical Services Price Target to $440 From $400, Maintains Overweight Rating MT
09-22 West Pharmaceutical Poised to See EPS Upside to Current 2027 Wall Street Estimates, Morgan Stanley Says MT
09-22 Morgan Stanley Upgrades West Pharmaceutical Services to Overweight From Equalweight, Adjusts PT to $400 From $365 MT
09-09 UBS Raises Price Target on West Pharmaceutical Services to $415 From $340, Keeps Buy Rating MT
07-27 Evercore ISI Adjusts PT on West Pharmaceutical Services to $425 From $410, Maintains Outperform Rating MT
07-27 BNP Paribas Adjusts PT on West Pharmaceutical Services to $459 From $447, Maintains Outperform Rating MT
07-24 Jefferies & Co Adjusts West Pharmaceutical Services PT to $410 From $365, Maintains Buy Rating MT
07-24 Rothschild & Co Redburn Adjusts West Pharmaceutical Services PT to $410 From $353, Maintains Buy Rating MT
07-24 Deutsche Bank Adjusts West Pharmaceutical Services Price Target to $420 From $405, Maintains Buy Rating MT
07-20 Stephens Adjusts West Pharmaceutical Services Price Target to $410 From $360, Maintains Overweight Rating MT
07-15 TD Cowen Adjusts Price Target on West Pharmaceutical Services to $410 From $365, Maintains Buy Rating MT
07-13 BNP Paribas Initiates West Pharmaceutical Services at Outperform With $447 Price Target MT
07-13 BNP Paribas Initiates West Pharmaceutical Services at Outperform With $447 Price Target MT
07-09 Morgan Stanley Adjusts Price Target on West Pharmaceutical Services to $365 From $325 MT
07-06 Evercore ISI Adjusts Price Target on West Pharmaceutical Services to $410 From $390 MT
07-02 KeyBanc Adjusts PT on West Pharmaceutical Services to $390 From $350, Maintains Overweight Rating MT
06-09 Barclays Upgrades West Pharmaceutical Services to Overweight From Equalweight, Adjusts PT to $400 From $310 MT
05-28 Morgan Stanley Adjusts West Pharmaceutical Services PT to $325 From $315, Keeps Equalweight Rating MT
04-24 Stephens Adjusts Price Target on West Pharmaceutical Services to $360 From $320, Maintains Overweight Rating MT
04-24 Deutsche Bank Adjusts West Pharmaceutical Services PT to $340 From $315, Maintains Buy Rating MT
04-24 Rothschild & Co Redburn Adjusts West Pharmaceutical Services Price Target to $353 From $312, Maintains Buy Rating MT
04-24 Jefferies Adjusts West Pharmaceutical Services Price Target to $365 From $295, Maintains Buy Rating MT
04-24 Citigroup Adjusts West Pharmaceutical Services PT to $400 From $375, Maintains Buy Rating MT
04-24 Evercore ISI Adjusts West Pharmaceutical Services PT to $390 From $320, Maintains Outperform Rating MT
04-24 TD Cowen Adjusts West Pharmaceutical Services PT to $365 From $350, Maintains Buy Rating MT

Consensus Analysts' recommendations evolution (4 months) Financial estimates divergence Analysts' Target price divergence Objective/dr gap
+20.62%
+19.17%
+28.67%
+57.3%
+17.25%
+23.27%
+8.76%
+33.06%
+9.87%
Average +24.22%
Weighted average by Cap. +24.82%


Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
17
Last Close Price
372.64USD
Average target price
411.00USD
Spread / Average Target
+10.29%
High Price Target
459.00USD
Spread / Highest target
+23.18%
Low Price Target
340.00USD
Spread / Lowest Target
-8.76%

Analyst Consensus Detail

Analyst consensus - West Pharmaceutical Services, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - West Pharmaceutical Services, Inc.
Trader
Investor
Global
Quality
ESG MSCI
-
Ratings Surperformance© - West Pharmaceutical Services, Inc.
  1. Stock Market
  2. Stocks
  3. WST Stock
  4. W2ST34 Stock
  5. Consensus West Pharmaceutical Services, Inc.